Literature DB >> 29345190

Magnetoelectric nanoparticles for delivery of antitumor peptides into glioblastoma cells by magnetic fields.

Tiffanie S Stewart1,2, Abhignyan Nagesetti1, Rakesh Guduru1, Ping Liang3, Emmanuel Stimphil1, Ali Hadjikhani1, Luis Salgueiro4, Jeffrey Horstmyer5, Renzhi Cai4, Andrew Schally4, Sakhrat Khizroev1,5.   

Abstract

AIM: We studied externally controlled anticancer effects of binding tumor growth inhibiting synthetic peptides to magnetoelectric nanoparticles (MENs) on treatment of glioblastomas.
METHODS: Hydrothermally synthesized 30-nm MENs had the core-shell composition of CoFe2O4@BaTiO3. Molecules of growth hormone-releasing hormone antagonist of the MIA class (MIA690) were chemically bound to MENs. In vitro experiments utilized human glioblastoma cells (U-87MG) and human brain microvascular endothelial cells.
RESULTS: The studies demonstrated externally controlled high-efficacy binding of MIA690 to MENs, targeted specificity to glioblastoma cells and on-demand release of the peptide by application of d.c. and a.c. magnetic fields, respectively.
CONCLUSION: The results support the use of MENs as an effective drug delivery carrier for growth hormone-releasing hormone antagonists in the treatment of human glioblastomas.

Entities:  

Keywords:  cancer/oncology; gene/drug delivery; nanoparticles

Mesh:

Substances:

Year:  2018        PMID: 29345190      PMCID: PMC5810849          DOI: 10.2217/nnm-2017-0300

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  51 in total

Review 1.  Applications of nanoparticles in cancer medicine and beyond: optical and multimodal in vivo imaging, tissue targeting and drug delivery.

Authors:  Stefania Biffi; Rebecca Voltan; Enrico Rampazzo; Luca Prodi; Giorgio Zauli; Paola Secchiero
Journal:  Expert Opin Drug Deliv       Date:  2015-08-09       Impact factor: 6.648

2.  The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues.

Authors:  Alexandre Havt; Andrew V Schally; Gabor Halmos; Jozsef L Varga; Gabor L Toller; Judit E Horvath; Karoly Szepeshazi; Frank Köster; Kevin Kovitz; Kate Groot; Marta Zarandi; Celia A Kanashiro
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-18       Impact factor: 11.205

3.  Uptake and transport of superparamagnetic iron oxide nanoparticles through human brain capillary endothelial cells.

Authors:  L B Thomsen; T Linemann; K M Pondman; J Lichota; K S Kim; R J Pieters; G M Visser; T Moos
Journal:  ACS Chem Neurosci       Date:  2013-08-26       Impact factor: 4.418

Review 4.  The neurobiology of gliomas: from cell biology to the development of therapeutic approaches.

Authors:  Manfred Westphal; Katrin Lamszus
Journal:  Nat Rev Neurosci       Date:  2011-08-03       Impact factor: 34.870

Review 5.  Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy.

Authors:  Xu Zhou; Renhe Liu; Shuo Qin; Ruilian Yu; Yao Fu
Journal:  Curr Drug Metab       Date:  2016       Impact factor: 3.731

6.  Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth.

Authors:  Marta Zarandi; Renzhi Cai; Magdolna Kovacs; Petra Popovics; Luca Szalontay; Tengjiao Cui; Wei Sha; Miklos Jaszberenyi; Jozsef Varga; XianYang Zhang; Norman L Block; Ferenc G Rick; Gabor Halmos; Andrew V Schally
Journal:  Peptides       Date:  2017-01-24       Impact factor: 3.750

7.  Inhibition of experimental U-118MG glioblastoma by targeted cytotoxic analogs of bombesin and somatostatin is associated with a suppression of angiogenic and antiapoptotic mechanisms.

Authors:  Celia A Kanashiro; Andrew V Schally; Attila Nagy; Gabor Halmos
Journal:  Int J Oncol       Date:  2005-07       Impact factor: 5.650

8.  Potentiating effects of GHRH analogs on the response to chemotherapy.

Authors:  Andrew V Schally; Roberto Perez; Norman L Block; Ferenc G Rick
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

9.  The application of magnetic nanoparticles for the treatment of brain tumors.

Authors:  Keon Mahmoudi; Costas G Hadjipanayis
Journal:  Front Chem       Date:  2014-12-03       Impact factor: 5.221

Review 10.  Targeted therapy using nanotechnology: focus on cancer.

Authors:  Vanna Sanna; Nicolino Pala; Mario Sechi
Journal:  Int J Nanomedicine       Date:  2014-01-15
View more
  6 in total

Review 1.  Recent advances, status, and opportunities of magneto-electric nanocarriers for biomedical applications.

Authors:  Nagesh Kolishetti; Arti Vashist; Adriana Yndart Arias; Venkata Atluri; Shanta Dhar; Madhavan Nair
Journal:  Mol Aspects Med       Date:  2021-11-04

Review 2.  Technobiology's Enabler: The Magnetoelectric Nanoparticle.

Authors:  Sakhrat Khizroev
Journal:  Cold Spring Harb Perspect Med       Date:  2019-08-01       Impact factor: 6.915

3.  Synthesis, Characterization, Anti-Cancer Analysis of Sr0.5Ba0.5DyxSmxFe8-2xO19 (0.00 ≤ x ≤ 1.0) Microsphere Nanocomposites.

Authors:  Suhailah S Al-Jameel; Munirah A Almessiere; Firdos A Khan; Nedaa Taskhandi; Yassine Slimani; Najat S Al-Saleh; Ayyar Manikandan; Ebtesam A Al-Suhaimi; Abdulhadi Baykal
Journal:  Nanomaterials (Basel)       Date:  2021-03-11       Impact factor: 5.076

Review 4.  Magnetic nanoparticles in theranostics of malignant melanoma.

Authors:  Maxim Shevtsov; Susanne Kaesler; Christian Posch; Gabriele Multhoff; Tilo Biedermann
Journal:  EJNMMI Res       Date:  2021-12-14       Impact factor: 3.138

Review 5.  Metal-Based Nanostructured Therapeutic Strategies for Glioblastoma Treatment-An Update.

Authors:  Agata M Gawel; Ravi Singh; Waldemar Debinski
Journal:  Biomedicines       Date:  2022-07-05

6.  Modeling of core-shell magneto-electric nanoparticles for biomedical applications: Effect of composition, dimension, and magnetic field features on magnetoelectric response.

Authors:  Serena Fiocchi; Emma Chiaramello; Alessandra Marrella; Giulia Suarato; Marta Bonato; Marta Parazzini; Paolo Ravazzani
Journal:  PLoS One       Date:  2022-09-23       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.